Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (5y) (2015 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10,030.00 |
| Mar 31, 2026 | 28,074.00 |
| Dec 31, 2025 | 4.22 Mn |
| Sep 30, 2025 | 65,501.00 |
| Jun 30, 2025 | 110,884.00 |
| Mar 31, 2025 | 46,611.00 |
| Dec 31, 2024 | 2,203.00 |
| Sep 30, 2024 | 156,868.00 |
| Jun 30, 2024 | 169,667.00 |
| Mar 31, 2024 | 40,206.00 |
| Dec 31, 2023 | 87,256.00 |
| Sep 30, 2023 | 238,810.00 |
| Jun 30, 2023 | 8,933.00 |
| Mar 31, 2023 | 42,586.00 |
| Dec 31, 2022 | 24,272.00 |
| Sep 30, 2022 | 10,103.00 |
| Jun 30, 2022 | 26,989.00 |
| Mar 31, 2022 | -6,626.00 |
| Dec 31, 2021 | -602.00 |
| Sep 30, 2021 | 17,081.00 |